AstraZeneca PLC (AZN)vsEnvista Holdings Corp (NVST)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
NVST
Envista Holdings Corp
$25.55
-1.24%
HEALTHCARE · Cap: $4.24B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2048% more annual revenue ($61.37B vs $2.86B). AZN leads profitability with a 17.0% profit margin vs 3.3%. AZN trades at a lower P/E of 24.3x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
NVST
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for NVST.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Earnings expanding 111.3% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
ROE of 2.2% — below average capital efficiency
3.3% margin — thin
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : NVST
The strongest argument for NVST centers on Price/Book, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : NVST
The primary concerns for NVST are Return on Equity, Profit Margin, P/E Ratio. A P/E of 45.5x leaves little room for execution misses. Thin 3.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while NVST is a value play — different risk/reward profiles.
NVST carries more volatility with a beta of 0.86 — expect wider price swings.
NVST is growing revenue faster at 7.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 54/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Envista Holdings Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Envista Holdings Corporation, develops, manufactures and markets dental products in the United States and internationally. The company is headquartered in Brea, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?